Symptomatic comparison in efficacy on patients with benign prostatic hyperplasia treated with two therapeutic approaches

Complementary Therapies in Medicine

Volumn 18, Issue 1, 2010, Pages 21-27

  Li, Shao ^a   Lu, Aiping ^b   Wang, Yongyan ^b  

^a TSINGHUA NATIONAL LABORATORY FOR INFORMATION SCIENCE AND TECHNOLOGY   (China)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

Benign prostatic hyperplasia; Comparative study; Efficacy; Symptom patterns; Traditional Chinese medicine

Indexed keywords

CHINESE DRUG; HERBAL SAXIFRAGE; TERAZOSIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHINESE MEDICINE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; MICTURITION; OUTCOME ASSESSMENT; PROSTATE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; URETHRA DISEASE;

AGED; ANTINEOPLASTIC AGENTS; HUMANS; LOGISTIC MODELS; MALE; MEDICINE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; PHYTOTHERAPY; PLANT PREPARATIONS; PRAZOSIN; PROSTATE; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUESTIONNAIRES; SAXIFRAGACEAE; URETHRA; URINATION;

EID: 77049116750     PISSN: 09652299     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctim.2009.10.002     Document Type: Article

References (30)

1. Smith R.A., Wake R., and Soloway M.S. Benign Prostatic Hyperplasia. Universal problem among aging men. Postgrad Med 83 (1988) 79-85
2. Basalingappa S., Ignatius J.X., and Madappa K.M. Clinical evaluation of prazosin in symptomatic benign prostatic hyperplasia - an Indian experience. Indian J Pharmacol 29 (1997) 420-425
3. Christensen M.M., and Bruskewitz R.C. Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention. Urol Clin North Am 17 (1990) 509-516
4. Portis A.J., and Mador D.R. Treatment options for benign prostatic hyperplasia. Can Fam Physician 43 (1997) 1395-1404
5. Robert Y., and Yuan L. Traditional Chinese medicine: an approach to scientific proof and clinical validation. Pharmacol Ther 86 (2000) 191-198
6. Yarnell E. Botanical medicines for the urinary tract. World J Urol 20 (2002) 285-293
7. Hou S.L., Cui Y., Ma A.L., Zhao J., Xu F.X., Yuan X.R., et al. Experimental study on effect of sanmiao mixture capsules on prostate hyperplasia in mice and rats. Zhongguo Zhong Yao Za Zhi 25 (2000) 110-114
8. Li S., Zhang Z., Wu L., Zhang X., Li Y., and Wang Y. Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network. IET Syst Biol 1 (2007) 51-60
9. State Bureau of Technical Supervision. Clinic terminology of traditional Chinese medical diagnosis and treatment-ZHENG (1997), Standards Press of China, Beijing p. 52
10. State Administration Bureau of TCM. Criteria of diagnosis and therapeutic effect of diseases and ZHENGs in traditional Chinese medicine (1994), Nanjing University Press, Nanjing p. 29
11. Price C.P. Application of the principles of evidence-based medicine to laboratory medicine. Clin Chim Acta 333 (2003) 147-154
12. Aso Y., and Homma Y. Clinical research criteria: response criteria for evaluating efficacy of treatments for benign prostatic hypertrophy. Br J Urol 76 (1995) 69-73
13. Gottdiener W.H., and Haslam N. A critique of the methods and conclusions in the patient outcome research team (PORT) report on psychological treatments for schizophrenia. J Am Acad Psychoanal Dyn Psychiatry 31 (2003) 191-208
14. Montazeri A., Milroy R., Hole D., McEwen J., and Gillis C.R. How quality of life data contribute to our understanding of cancer patients' experiences? A study of patients with lung cancer. Qual Life Res 12 (2003) 157-166
15. Plante M., Corcos J., Gregoire I., Belanger M.F., Brock G., and Rossingol M. The international prostate symptom score: physician versus self-administration in the quantification of symptomatology. Urology 47 (1996) 326-328
16. Werneke U., Goldberg D.P., Yalcin I., and Ustun B.T. The stability of the factor structure of the General Health Questionnaire. Psychol Med 30 (2000) 823-829
17. Ventegodt S., Henneberg E., Merrick J., and Lindholt J. Validation of two global and generic quality of life questionnaires for population screening: SCREENQOL and SEQOL. Sci World J 3 (2003) 412-421
18. Li S., Lu A.P., Zhang L., and Li Y.D. Anti-Helicobacter pylori immunoglobulin G (IgG) and IgA antibody responses and the value of clinical presentations in diagnosis of H. pylori infection in patients with precancerous lesions. World J Gastroenterol 9 (2003) 754-758
19. Li S., Wang R., Zhang Y., Zhang X., Layon A.J., Li Y., et al. Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS. Am J Chinese Med 34 (2006) 937-947
20. Hillman A.L., Schwartz J.S., Willian M.K., Peskin E., Roehrborn C.G., Oesterling J.E., et al. The cost-effectiveness ofterazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology 47 (1996) 169-178
21. Chow G.C. Tests of equality between sets of coefficients in two linear regressions. Econometrica 28 (1960) 591-605
22. Ding J.X., Zhang Q.H., and Zhang L. Measurement of Bergenin from Herbal Saxifragae of different producing areas and different harvest periods by HPLC method. Zhongguo Zhong Yao Za Zhi 27 (2002) 792-794
23. Takahashi H., Kosaka M., Watanabe Y., Nakade K., and Fukuyama Y. Synthesis and neuroprotective activity of bergenin derivatives with antioxidant activity. Bioorg Med Chem 11 (2003) 1781-1788
24. Lim H.K., Kim H.S., Choi H.S., Choi J., Kim S.H., and Chang M.J. Effects of bergenin, the major constituent of Mallotus japonicus against d-galactosamine-induced hepatotoxicity in rats. Pharmacology 63 (2001) 71-75
25. Roehrborn C.G., Oesterling J.E., Auerbach S., Kaplan S.A., Lloyd L.K., Milam D.E., et al. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 47 (1996) 159-168
26. Grayhack J.T. Benign prostatic hyperplasia. The scope of the problem. Cancer 70 (1992) 275-279
27. Studinger P., Goldstein R., and Taylor J.A. Mechanical and neural contributions to hysteresis in the cardiac vagal limb of the arterial baroreflex. J Physiol 583 (2007) 1041-1048
28. Locca J.F., Ruggli M., Buchmann M., Huguenin J., and Bugnon O. Development of pharmaceutical care services in nursing homes: practice and research in a Swiss canton. Pharm World Sci 31 (2009) 165-173
29. Ohtani K., and Toyoda T. Small sample properties of tests of equality between sets of coefficients in two linear regressions under heteroscedasticity. Int Econ Rev 26 (1985) 37-44
30. Li S. Network systems underlying traditional Chinese medicine syndrome and herb formula. Curr Bioinform 4 (2009) 188-196